412 related articles for article (PubMed ID: 15831674)
1. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
3. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
4. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
5. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
6. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Walker G; MacLeod K; Williams AR; Cameron DA; Smyth JF; Langdon SP
Gynecol Oncol; 2007 Sep; 106(3):461-8. PubMed ID: 17624412
[TBL] [Abstract][Full Text] [Related]
8. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
10. Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor.
Wang Y; Hu L; Yao R; Wang M; Crist KA; Grubbs CJ; Johanning GL; Lubet RA; You M
Oncogene; 2001 Nov; 20(53):7710-21. PubMed ID: 11753649
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
12. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
13. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
14. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
15. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
Frasor J; Chang EC; Komm B; Lin CY; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
Cancer Res; 2006 Jul; 66(14):7334-40. PubMed ID: 16849584
[TBL] [Abstract][Full Text] [Related]
16. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Brodie A; Jelovac D; Long BJ
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
[TBL] [Abstract][Full Text] [Related]
17. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
19. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines.
Ramachandran C; Rodriguez S; Ramachandran R; Raveendran Nair PK; Fonseca H; Khatib Z; Escalon E; Melnick SJ
Anticancer Res; 2005; 25(5):3293-302. PubMed ID: 16101141
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
